CD33 and acute myeloid leukemia: The field reached its first regulatory milestone in 2000 with the FDA approval of gemtuzumab ozogamicin (Mylotarg®), an anti-CD33 ADC for acute myeloid leukemia, which used a hydrazone linker to connect a humanized mAb to the DNA-damaging agent calicheamicin [22].